Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2016 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Proceedings of the 3rd IPLeiria's International Health Congress : Leiria, Portugal. 6-7 May 2016.
BMC Health Serv Res. 2016 Jul 6;16 Suppl 3(Suppl 3):200. doi: 10.1186/s12913-016-1423-5.
BMC Health Serv Res. 2016.
PMID: 27409075
Free PMC article.
Padilha, Jorge Valente O92 Multimodal acute pain management during uterine artery embolization in treatment of uterine myomas Jose T. Guerrero, Francisco P. Caballero, Rafael B. Santos, Estefania P. Gonzalez, Fatima M. ...Castuera, Helena Mesquita, Antonio Fa …
Padilha, Jorge Valente O92 Multimodal acute pain management during uterine artery embolization in treatment of uterine myomas Jose T. Guerre …
Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB).
Sassaki LY, Magro DO, Saad-Hossne R, Baima JP, Flores C, Correia LM, Celani LMS, De Abreu Ferrari ML, Zacharias P, Feitosa MR, Dos Santos CHM, De Freitas Lins Neto MA, Quaresma AB, De Lima Junior SF, De Vasconcelos GBS, Cassol OS, Dos Santos Pinto A, Kurachi G, Goncalves Filho FA, Gasparini RG, Furlan TK, Catapani WR, Coy CSR, De Souza Menegassi V, Colombo MM, Fróes RSB, Teixeira FV, Moraes AC, Santana GO, Parente JML, Vilela EG, Queiroz NSF, Kotze PG; GEDIIB (Brazilian Study Group of IBD).
Sassaki LY, et al.
BMC Gastroenterol. 2022 May 29;22(1):268. doi: 10.1186/s12876-022-02341-7.
BMC Gastroenterol. 2022.
PMID: 35644668
Free PMC article.
Remission rates were higher in the IFX group at weeks 26 (75.12% vs. 62.65%, p < 0.0001) and 52 (65.24% vs. 51.35%, p < 0.0001) when compared to ADA. According to Kaplan-Meier survival curve loss of response was less frequent in the Infliximab compared to Adal
…Remission rates were higher in the IFX group at weeks 26 (75.12% vs. 62.65%, p < 0.0001) and 52 (65.24% vs. 51.35%, p <
…
Item in Clipboard
Cite
Cite